Omega Diagnostics Share Discussion Threads

[rivaldo] 12/10/2016 09:33

Big coverage everywhere today about the huge increase in allergic reactions and anaphylactic shocks:



An amazing statistic here - which must be good news for ODX:

"Data about how many people in the UK suffer from an allergy is not conclusive but the charity Allergy UK claims that up to 50% of children are now diagnosed with an allergic condition"

[barrywhit] 30/9/2016 15:18

Disappointing, never seems to hold onto any gains, investors get fed up waiting. I thought we were close to CE Approval on the allergy system, really need an update...

[p1nkfish] 18/9/2016 00:26

I have been adding too, averaged up..

[the big fella] 15/9/2016 21:55

I bought more yesterday and today.

[barrywhit] 15/9/2016 20:44

A lot of late large trades showing over the last couple of days.......Oryx offloading their remainder...

[arthur_lame_stocks] 25/8/2016 14:32

I bought more today, I think this is an opportunity.

[shanklin] 25/8/2016 14:18

Interesting commentary on the sector from HL's midday report today, ...

(ShareCast News) - UK equities were dragged lower by pharmaceutical shares on Thursday following remarks from US presidential candidate Hillary Clinton on cutting prices of medication.

Clinton joined senators Susan Collins and Claire McCaskill in highlighting US-based Mylan's 480% hike in the price of its EpiPen epinephrine product since the company acquired it in 2007.

Sending signals about the potential direction of drug policy if she wins the presidential race, Clinton called on Mylan to drop the price of EpiPen, which has leapt from $100 for a two-pack in 2007 to around $600 today.

Her comments on Mylan hit shares of sector peers including FTSE 100 listed drug makers Hikma Pharmaceuticals, Shire and AstraZeneca.

Analyst Mike van Dulken at Accendo Markets said Clinton's comments serve to "strike fear into the hearts of healthcare groups and their investors everywhere".

"As always, the industry remains between a rock and a hard place, treading the fine line between balancing the costs of clinical success (and failure) with the economic laws of supply and demand, all the while trying (often in vain) to satisfy demanding stakeholders without appearing to view the sick as merely a commercial opportunity."

[hyperboreus] 25/8/2016 14:14

Increase in headcount regarding Allersys and growth in Food Intolerance business will inevitably affect profits despite the increase in sales for this year.

Any positive news regarding Visitect field trials might give the share price a boost but unless something 'unexpected' occurs, good or bad, I reckon Omega is fairly valued at these levels for the time being as commercial revenues from Visitect are not likely until some time in 2018 assuming all goes well.

[rivaldo] 25/8/2016 13:41

Volumes have actually been tiny, with less than £100k traded in the last 5 trading days and only one trade over 100k shares, which suggests it's really just summer boredom and illiquidity.

However, it's worth noting that Finncap are forecasting 0.8p EPS, reduced from the previous (from memory) 1.3p-1.4p due to greater write-offs to P&L this year of expenditure on CD4, Allersys etc. Of course the core business should still produce 1.3p+ EPS - and possibly more given currency gains this year - but perhaps a few small holders have been panicked out.

[longshanks] 25/8/2016 13:34

Wouldn't be surprised if Oryx were reducing to zero; if so, they can't have too many left by my estimation.I sold some on the recent spike but am back to buying now.From experience, the wholesale dumping of illiquid stocks by institutions provides excellent buying opportunities.

[shanklin] 25/8/2016 13:17

Added a few at 16.75 just after the bid started moving up. Lets hope that proves to be a good idea.

[barrywhit] 25/8/2016 13:11

Is the seller Oryx Int. Growth Fund, they offloaded 2million of which the majority was bought by Richard Sneller, perhaps they are offloading the rest, they held 3million (2.76%).....they only purchased their holding in December 2015....may not be them, just a thought..........

[longshanks] 25/8/2016 10:36

we have had a heavy seller in recent days so I wouldn't read too much into it.

I am buying more and I am sure others will.

Can't see a fundraising being required as they have been generating sufficient cash over the last few years to support a fairly heavy development program. Much of that R&D cost should be now coming towards an end as those products become commercialised and in turn begin generating revenues.

They do though need to fund the project to extend Allersys to cover 120 allergens (from the current 41) over the next three years. They have the £1.8m grant to assist but I would expect the rest of the financing to come in large part from income generated through sales of the Allersys systems rather than additional shareholder financing.

[geraldus] 25/8/2016 10:00

Possibly more funding in the wings on the back of recent strength?

[shanklin] 25/8/2016 09:55

By far my smallest holding but does anybody know a reason for the current share price weakness... ...other than more sellers than buyers in the shares?

[longshanks] 24/8/2016 13:11

I hadn't realised how active ODX is on Twitter.They have posted some interesting tweets through August indicating some positive developments:They retweeted a post by the Burnett institute this morning after having posted this tweet themselves earlier in the month about testing of visitect CD4 with the UN in DRC (reported from Durban, SA).hTTps://mobile.twitter.com/OmegaDiagnostic/status/764046407741300736They also have tweeted three new positions - presumably linked to the recent grant for further development of the Allersys system.

[verger] 09/8/2016 17:25

Organic growth will be gentle and positive. The excitement will come from deals and launches that have been promised.

[longshanks] 09/8/2016 16:38

Might have to wait a while longer....

[verger] 09/8/2016 09:56

I'm ready, but please don't rush me. Can we go up to 24p first before we head towards 30p? Thanks.

[leedslad001] 03/8/2016 08:53

Sit back and enjoy the ride

[rivaldo] 03/8/2016 07:33

According to today's Daily Mail, yesterday's grant win was actually for £1.8 BILLION....:o))



"Omega Diagnostics, a medical firm which focuses on allergies, food intolerance and infectious disease, soared after it secured funding for research and development.

The business has a £1.8billion Scottish Enterprise grant, which should help to fund the expansion of its Allersys range over the next three years so it covers 120 allergens rather than the current 41. Shares advanced 8.3 per cent, or 1.5p to 19.5p."

[longshanks] 02/8/2016 17:19

Wonderful bit of affirmation today for all holders that have held long and strong with this.I was responsible for a sale today 20k @19.4. Needed some funds for my rather expensive holiday; happy to run the bulk of my holdings though as this has a long way to go yet to reach fair value.

[p1nkfish] 02/8/2016 17:00

Should fly off the shelves too.
Sneller is also in crx, another piece of good news today.